2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
I

Targeting Exon 20 Insertions in NSCLC: Anti-Tumor Activity With T-Dxd in HER2m Disease, Assessing Efficacy of Treatment Options in EGFRm Disease

By 2020 ASCO Virtual Direct™ Highlights FEATURING Ibiayi Dagogo-Jack
By 2020 ASCO Virtual Direct™ Highlights FEATURING Ibiayi Dagogo-Jack
327 views
January 28, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

05:59
Lilly Medical Affairs

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy

Featured Video

06:14
Lilly Medical Affairs

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy
Lung
13:52

Targeting Exon 20 Insertions in NSCLC: Anti-Tumor Activity With T-Dx…

2020 ASCO Virtual Direct™ Highlights

I. Dagogo-Jack

327 views
18:53

2020 ASCO Update on 1L Treatment of ES-SCLC: IO + Chemo - Results fr…

2020 ASCO Virtual Direct™ Highlights

N. Seetharamu

255 views
10:35

2020 ASCO Update on NSCLC: Neoadjuvant Chemo for Locally Advanced Di…

2020 ASCO Virtual Direct™ Highlights

N. Seetharamu

95 views
22:55

2020 ASCO Update on 1st Line IO Strategies for Metastatic NSCLC: Sho…

2020 ASCO Virtual Direct™ Highlights

I. Dagogo-Jack

740 views